Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo

Bertha K. Madras, Michele A. Fahey, Martin Goulet, Zhicheng Lin, Jacob Bendor, Claudia Goodrich, Peter C. Meltzer, David R. Elmaleh, Eli Livni, Ali A. Bonab and Alan J. Fischman
Journal of Pharmacology and Experimental Therapeutics November 2006, 319 (2) 570-585; DOI: https://doi.org/10.1124/jpet.106.105312
Bertha K. Madras
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele A. Fahey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Goulet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhicheng Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob Bendor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia Goodrich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter C. Meltzer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Elmaleh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eli Livni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali A. Bonab
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan J. Fischman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Viable dopamine neurons in Parkinson's disease express the dopamine transporter (DAT) and release dopamine (DA). We postulated that potent DAT inhibitors, with low affinity for the serotonin transporter (SERT), may elevate endogenously released extracellular dopamine levels to provide therapeutic benefit. The therapeutic potential of eight DAT inhibitors was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated cynomolgus monkeys (Macaca fascicularis), with efficacy correlated with DAT occupancy as determined by positron emission tomography imaging in striatum. Four potent DAT inhibitors, with relatively high norepinephrine transporter, but low SERT affinities, that occupied the DAT improved activity in parkinsonian monkeys, whereas three high-affinity DAT inhibitors with low DAT occupancy did not. 2β-Carbomethoxy-3α-(3,4-dichlorophenyl)-7β-hydroxy-8-methyl-8-azabicyclo[3.2.1.]octane (O-1163) occupied the DAT but had short-lived pharmacological effects. The benztropine analog difluoropine increased general activity, improved posture, reduced body freeze, and produced sleep disturbances at high doses. (1R)-2β-(1-Propanoyl)-3α-(4-fluorophenyl)tropane (O-1369) alleviated parkinsonian signs in advanced parkinsonian monkeys, by increasing general activity, improving posture, reducing body freeze, and sedation, but not significantly reducing bradykinesia or increasing locomotor activity. In comparison with the D2-D3 DA receptor agonist quinelorane, O-1369 elicited oral/facial dyskinesias, whereas quinelorane did not improve posture or reduce balance and promoted stereotypy. In conclusion, DAT inhibitors with therapeutic potential combine high DAT affinity in vitro and high DAT occupancy of brain striatum in vivo with enduring day-time effects that do not extend into the nighttime. Advanced parkinsonian monkeys (80% DAT loss) respond more effectively to DAT inhibitors than mild parkinsonian monkeys (46% DAT loss). The therapeutic potential of dopamine transport inhibitors for Parkinson's disease warrants preclinical investigation.

Footnotes

  • This study was supported by National Institutes of Health Grants NS30556 (NINDS), DA11558 and DA06303 (NIDA), and RR00168 (NCRR) and Boston Life Sciences, Inc. (Hopkinton, MA). The receptor-screening program was supported in part by the National Institute of Mental Health Psychoactive Drug Screening Program Grant NO1 MH80005.

  • This study was presented in abstract form. Madras BK (2001) Occupancy of the dopamine transporter by a transport inhibitor, as measured by PET imaging, is predictive of therapeutic efficacy for parkinsonism. J Nucl Med42 (Suppl):210P; Madras BK (2002) The therapeutic potential of a dopamine transport (DAT) inhibitor for Parkinson's disease: comparison with a D2 dopamine agonist in MPTP-treated monkeys. Society for Neuroscience, Washington, DC.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.106.105312.

  • ABBREVIATIONS: PD, Parkinson's disease; DAT, dopamine transporter; DA, dopamine; GBR 12909, 1-{2-[bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; CFT (WIN 35,428), 2β-carbomethoxy-3β-4-(fluorophenyl)-tropane; SERT, serotonin transporter; NET, norepinephrine transporter; difluoropine or O-620, (S)-(+)-2β-carbomethoxy-3α-(di-4-fluorophenylmethoxy)tropane; O-1369, (1R)-2β-(1-propanoyl)-3α-(4-fluorophenyl)tropane; O-1014, 2-carbomethoxy-3-(3,4-dichlorophenyl)-8-oxabicyclo[3.2.1]oct-2-ene; O-1163, 2β-carbomethoxy-3α-(3,4-dichlorophenyl)-7β-hydroxy-8-methyl-8-azabicyclo[3.2.1.]octane; O-1231, 2-carbomethoxy-3-(3,4-dichlorophenyl)bicyclo[3.2.1]oct-2-ene; O-1973, 2β-(1-propanoyl)-3α-(4-chlorophenyl)-8-oxabicyclo[3.2.1]octane; O-2099, 2β-(1-propanoyl)-3α-(3,4-dichlorophenyl)-7β-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane; O-2240, 2β-(1-propanoyl)-3α-(3,4-dichlorophenyl)-7β-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane laurate; PET, positron emission tomography; Ctrl, control; veh, vehicle; BTS 74 398, (1-[1-(3,4-dichlorophenyl)cyclobutyl]-2-(3-diaminethylaminopropylthio)ethanone monocitrate; NS 2330, tesofensine.

  • ↵1 Current affiliation: EnVivo Pharmaceuticals, Watertown, Massachusetts.

  • ↵2 Current affiliation: Laboratory of Cellular Molecular Neurosciences, Rockefeller University, New York, New York.

    • Received March 27, 2006.
    • Accepted August 1, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 376 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 376, Issue 2
1 Feb 2021
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo

Bertha K. Madras, Michele A. Fahey, Martin Goulet, Zhicheng Lin, Jacob Bendor, Claudia Goodrich, Peter C. Meltzer, David R. Elmaleh, Eli Livni, Ali A. Bonab and Alan J. Fischman
Journal of Pharmacology and Experimental Therapeutics November 1, 2006, 319 (2) 570-585; DOI: https://doi.org/10.1124/jpet.106.105312

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNEUROPHARMACOLOGY

Dopamine Transporter (DAT) Inhibitors Alleviate Specific Parkinsonian Deficits in Monkeys: Association with DAT Occupancy in Vivo

Bertha K. Madras, Michele A. Fahey, Martin Goulet, Zhicheng Lin, Jacob Bendor, Claudia Goodrich, Peter C. Meltzer, David R. Elmaleh, Eli Livni, Ali A. Bonab and Alan J. Fischman
Journal of Pharmacology and Experimental Therapeutics November 1, 2006, 319 (2) 570-585; DOI: https://doi.org/10.1124/jpet.106.105312
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Oxysterols and ethanol
  • P-glycoprotein Apical Efflux Ratio for Compound Optimization
  • Pharmacology of Carbamate Insecticides at MT1 & MT2
Show more Neuropharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics